Colorectal cancer: Cetuximab, KRAS, BRAF, PIK3CA mutations and beyond

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 5, 2010, Pages 525-529

  Katsios, Christos ^a   Ziogas, Dimosthenis E ^a   Roukos, Dimitrios H ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

BRAF; cancer genome; cetuximab; chemotherapy; colorectal cancer; genetic and environment interactions; KRAS; survival

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHOTRANSFERASE; PROTEIN PIK3CA; UNCLASSIFIED DRUG;

CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; MUTATIONAL ANALYSIS; PATIENT SELECTION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GENETIC TESTING; GENOTYPE; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PATIENT SELECTION; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TREATMENT OUTCOME;

EID: 77958023788     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.62     Document Type: Editorial

References (40)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J. Clin. DOI: 10.3322/caac.20073 (2010) (Epub ahead of print).
2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N. Engl. J. Med. 352(5), 476-487 (2005).
3. Sargent D, Sobrero A, Grothey A et al. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 27(6), 872-877 (2009).
4. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
5. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360(6), 563-572 (2009).
6. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
7. Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27(5), 672-680 (2009).
8. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663-671 (2009).
9. Tol J, Dijkstra JR, Klomp M et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur. J. Cancer 46(11), 1997-2009 (2010).
10. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 11(8), 753-762 (2010).
11. Stafford RS, Wagner TH, Lavori PW. New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N. Engl. J. Med. 361(13), 1230-1233 (2009).
12. Bastiaens P. Systems biology: When it is time to die. Nature 459(7245), 334-335 (2009).
13. Human genome at ten: The sequence explosion. Nature 464(7289), 670-671 (2010).
14. Ledford H. Big science: The cancer genome challenge. Nature 464(7291), 972-974 (2010).
15. The human genome at ten. Nature 464 (7289), 649-650 (2010).
16. Check Hayden E. Human genome at ten: Life is complicated. Nature 464(7289), 664-667 (2010).
17. Collins F. Has the revolution arrived? Nature 464(7289), 674-675 (2010).
18. Venter JC. Multiple personal genomes await. Nature 464(7289), 676-677 (2010).
19. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 458(7239), 719-724 (2009).
20. Stephens PJ, McBride DJ, Lin ML et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462(7276), 1005-1010 (2009).
21. Beroukhim R, Mermel CH, Porter D et al. The landscape of somatic copy-number alteration across human cancers. Nature 463(7283), 899-905 (2010).
22. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57-70 (2000).
23. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2(5), 331-341 (2002).
24. Roukos DH. Systems medicine: A real approach for future personalized oncology? Pharmacogenomics 11(3), 283-287 (2010).
25. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 461(7261), 218-223 (2009).
26. Rockman MV. Reverse engineering the genotype-phenotype map with natural genetic variation. Nature 456, 738-744 (2008).
27. Katsios C, Roukos DH. Individual genomes and personalized medicine: Life diversity and complexity. Per. Med. 7(4), 347-350(2010).
28. Roukos DH. Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn. 10(3), 247-250 (2010).
29. Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: A promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev. Mol. Diagn. 10(5), 541-545 (2010).
30. Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8), 1039-1043 (2010).
31. Roukos DH. Next-generation, genome sequencing-based biomarkers: Concerns and challenges for medical practice. Biomark. Med. 4(4), 583-586 (2010).
32. Wood SN. Statistical inference for noisy nonlinear ecological dynamic systems. Nature 466, 1102-1104 (2010).
33. Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007).
34. Powell SM, Zilz N, Beazer-Barclay Y et al. APC mutations occur early during colorectal tumorigenesis. Nature 359(6392), 235-237 (1992).
35. Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev. Mol. Diagn. 10(1), 33-48 (2010).
36. Roukos DH. Targeting gastric cancer with trastuzumab: New clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol. 17, 14-17 (2010).
37. Roukos DH, Tzakos A, Zografos G. Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev. Anticancer Ther. 9(10), 1413-1416 (2009).
38. Roukos DH. Breast cancer outcomes: The crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann. Surg. 249(6), 1067-1068 (2009).
39. Ziogas D, Roukos DH. Genetics and personal genomics for personalized breast cancer surgery: Progress and challenges in research and clinical practice. Ann. Surg. Oncol. 16(7), 1771-1782 (2009).
40. Roukos DH. Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann. Surg. Oncol. 16(4), 795-798 (2009).